Available drugs and supplements for rapid deployment for treatment of COVID-19

• Type of Material: Article
• Authors: Danielle Cicka, Emory University; Vikas Sukhatme, Emory University
• Language: English
• Date: 2021-01-25
• Publisher: OXFORD UNIV PRESS
• Publication Version: Final Published Version
• Copyright Statement: © The Author(s) (2021).
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1093/jmcb/mjab002
• Title of Journal or Parent Work: JOURNAL OF MOLECULAR CELL BIOLOGY
• Volume: 13
• Issue: 3
• Start Page: 232
• End Page: 236
• Grant/Funding Information: D.C. was supported by NIH training grant T32-GM008602
• Keywords: Cell Biology; SARS-CoV-2 infection; COVID-19; Science & Technology; Life Sciences & Biomedicine
• Research Categories: Health Sciences, Public Health; Health Sciences, Pharmacology

Abstract

Effective treatment for COVID-19 remains elusive, though urgently needed in the current pandemic. Repurposing marketed therapies may be an effective strategy for finding treatments quickly and recently, in vitro and clinical testing of such therapies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has skyrocketed. However, not all marketed drugs showing in vitro efficacy could achieve therapeutic concentrations in humans and discernment of drugs that have favorable pharmacokinetic properties can save time and resources for future studies. Here, we compile marketed therapies, including supplements, having antiviral activity with in vitro, in vivo, and/or clinical data against α and β coronaviruses into tables, alongside their pharmacokinetic properties. We point to several drugs or supplements available for immediate repurposing because they have achievable blood concentrations in humans well above their inhibitory concentrations against coronaviruses. This compilation may contribute to the implementation of rapid future studies by narrowing the vast number of marketed drugs reported for potential efficacy against SARS-CoV-2 on the basis of their pharmacokinetic properties and published coronavirus data.